Bringing the fundamentals into focus…
Back to Alnylam Pharmaceuticals, Inc.
How Alnylam Pharmaceuticals, Inc. stacks up
ALNY · against 552 other Healthcare companies listed in US-listed
Overall
67/ 100
Near the top of its peers.
Ranked #54 of 553 · scores higher than 89% of peers
Bars: peers in each 10-point band of the overall score63 peers with an overall score of 60–69, including ALNY · Click a bar to see the companies
The four scores behind it
Overall = average of valuation, growth, profitability and safety percentile (categories without data are skipped)Ranking by overall score
Top 5 and the companies ranked around ALNY| Rank | Company | Market cap | Overall | Valuation | Growth | Profitability | Risk |
|---|---|---|---|---|---|---|---|
| 1 | 595M USD | 97 | 96 | 98 | 99 | 0 / 2 | |
| 1 | 261M USD | 97 | 93 | — | 98 | 0 / 2 | |
| 3 | 2.1B USD | 96 | 96 | 99 | 93 | 0 / 2 | |
| 4 | 1.5B USD | 93 | 94 | 91 | 93 | 0 / 2 | |
| 5 | 609M USD | 91 | 95 | 99 | 99 | 0 / 2 | |
| 51 | 1.9B USD | 68 | 45 | 87 | 64 | 0 / 2 | |
| 51 | 5.8B USD | 68 | 54 | 50 | 95 | 0 / 2 | |
| 51 | 100.2B USD | 68 | 61 | 49 | 85 | 0 / 2 | |
| 54 | 301M USD | 67 | 92 | 77 | 95 | 2 / 2 | |
| 54 | 21.4B USD | 67 | 60 | 97 | 97 | 2 / 2 | |
| 54 | 1.2B USD | 67 | 61 | 80 | 36 | 0 / 2 | |
| 54 | 97.5B USD | 67 | 87 | 72 | 89 | 2 / 2 | |
| 54 | 8.4B USD | 67 | 57 | 71 | 83 | 1 / 2 | |
| 54 | 7.4B USD | 67 | 58 | 90 | 81 | 1 / 2 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score